Neuroendocrine Cancer Market

• Neuroendocrine Cancer market is growing with rising number of type of neuroendocrine cancer cases like Merkel cell cancer (MCC), Carcinoid Cancers, islet cell Cancers, medullary thyroid cancer, pheochromocytomas, small cell lung cancer, and others. For the treatment of these cancers, several studies are conducting to introduce new drugs into the market.
• For instance, in Mar 2017, the U.S. FDA approved avelumab (Bavencio) to treat patients 12 and older with Merkel cell cancer (MCC) that has spread to another part of the body.

Neuroendocrine Cancer Market Clinical Trial Analysis

• Total Neuroendocrine Cancer Studies: 2499

By Drug Type

•  Everolimus
•  Sunitinib Malate
•  Lanreotide
•  Octreotide
•  Others

Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of neuroendocrine cancer.

Treatment

•  Surgery
•  Chemotherapy
•  Targeted Therapy
•  Radiotherapy
•  Other Medications

The operation is the primary treatment for Neuroendocrine cancer accounted for the largest market share followed by Chemotherapy.

By End User

•  Hospitals
•  Oncology Centers
•  Others

• The market is segmented geographically into North America, South America, Europe, Asia-Pacific, and RoW. North America is dominating the global Neuroendocrine cancer market.
• According to Cancer.Net, approx. It is estimated that more than 12,000 people in the United States are diagnosed with a neuroendocrine tumor each year. Also, several major players in neuroendocrine cancer market are based in the U.S and therefore consider North America is a has the highest market share with new product launch and research and development investments. With the rising prevalence of neuroendocrine cancer in the Asia-Pacific, the market is growing at the highest CAGR.
• The major players of global Neuroendocrine Cancer market include Advanced Accelerator Applications, Novartis AG, Hutchison Medipharma Ltd, Dauntless Pharmaceuticals Inc., Aspen, Tarveda Therapeutics, Exelixis, and Pfizer Inc.Some recently approved drugs for the treatment of Neuroendocrine Cancer are:
• In Jan 2018, Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US FDA approval of its new drug application (NDA) for Lutathera® for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.

Target Audience

•  Raw Material Suppliers/ Buyers
•  Product Suppliers/ Buyers
•  Industry Investors/Investment Bankers
•  Education & Research Institutes
•  Research Professionals
•  Emerging Companies
•  Manufacturers

Why purchase the report?

•  Visualize the composition of the Global Neuroendocrine Cancer market across each indication, regarding type and applications, highlighting the critical commercial assets and players.
•  Identify commercial opportunities in Global Neuroendocrine Cancer by analyzing trends and co-development deals.
•  Excel data sheet with thousands of data points in the Global Neuroendocrine Cancer market – level 4/5 segmentation
•  PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
•  Product mapping in excel for the critical Global Neuroendocrine Cancer products of all major market players